Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial - PubMed
7 hours ago
- #PCOS
- #Metformin
- #Randomized Controlled Trial
- The MET-PCOS trial aims to optimize metformin use in PCOS by comparing doses of 1500 mg/day and 2250 mg/day.
- PCOS affects 11-13% of women of reproductive age and is linked to reproductive, metabolic, endocrine, and mental health issues.
- Lifestyle changes are first-line treatment, but metformin is recommended for those with BMI ≥25 kg/m².
- The study is a double-blind randomized controlled trial with 184 participants aged 18-37, meeting Rotterdam criteria for PCOS.
- Outcomes include metabolic markers, hyperandrogenism, ovarian morphology, menstrual cyclicity, mental health, and gastrointestinal effects.
- Measurements will be taken at baseline, 14 weeks, and 26 weeks.
- The trial is approved by Finnish regulatory bodies and aims to guide optimal metformin dosing in PCOS.
- Trial registration numbers: NCT07120815 and EU 2023-509259-15-01.